Why the study?
Does delayed administration of dexrazoxane reduce cardiac events and congestive heart failure in patients with advanced breast cancer treated with doxorubicin-containing therapy?
Does delayed administration of dexrazoxane reduce cardiac events and congestive heart failure in patients with advanced breast cancer treated with doxorubicin-containing therapy?
Delayed administration of dexrazoxane after a cumulative doxorubicin dose of 300 mg/m2 provides significant cardioprotection against congestive heart failure in patients with advanced breast cancer.
No takes yet. Share an insight, caveat, or question.
Delayed dexrazoxane may reduce CHF risk after 300 mg/m² doxorubicin; leaves open need for randomized confirmation before practice change.
Swain et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: